Avoid common mistakes on your manuscript.
The 15th biannual International Congress of the International Society of Cardiovascular Pharmacotherapy (ISCP) will be held on October 11–12, 2009 in Beijing in collaboration with the annual Great Wall International Congress of Cardiology.
An exciting structured program has been finalized covering a wide range of contemporary issues in drug therapy for cardiovascular diseases. A feature of the program will be the Henry Neufeld Memorial Lecture given this year by Juan Carlos Kaski, Vice-President of ISCP. Poster sessions of selected submitted abstracts will provide an opportunity for wider participation. Young Investigator Awards will be bestowed on those abstracts from young researchers selected for excellence by a review committee.
The program for the meeting is shown below.
Jay N. Cohn, M.D, President
THE 15TH INTERNATIONAL CONGRESS ON CARDIOVASCULAR PHARMACOTHERAPY
Program
SUNDAY, OCTOBER 11, 2009
Drugs to Reduce Cardiovascular Risk
Co-chair: Jay N. Cohn
Co-chair: Zhu Junren
8:00 Role of endothelium in vascular and cardiac injury
Paul Vanhoutte
8:20 Lipid lowering drugs for primary and secondary prevention
Rodolfo Paoletti
8:40 Anti-hypertensive therapy: Who is at risk and what is optimal therapy?
William Louis
9:00 Should high-risk patients receive anti-thrombotic therapy and which one?
Nicolas Danchin
9:20 Modern advances in anti-smoking therapy
John McNeil
9:40 Neufeld Lecture
Atheromatous plaque regression
Juan Carlos Kaski
10:15 Break
Joint ISCP-GWIIC Program
Co-chair: Willliam Louis
Co-chair: Huo Yong
10:45 CONSIDER – Survey on Cardiovascular Risk Factors in Hypertensive Patients in China
Zhao Dong
11:05 Management of hypertension: From hypertensive guidelines to clinical practice
Wang Jiguang
11:25 Statins: The cornerstone of anti-atherosclerosis treatment
Zhao Shuiping
11:45 Cholesterol management recommendations for hypertensive patients
Zhang Weizhong
12:05 Lunch
Neurohormonal Inhibition in Cardiovascular Therapy
Co-chair: Dennis Cokkinos
Co-chair: Yan Xiaowei
1:30 The renin-angiotensin system
Jay N. Cohn
1:50 Aldosterone inhibition and cardiovascular protection: More important than it once appeared
Felipe Martinez
2:10 Which beta blocker is most effective in heart failure?
Willem Remme
Drug Treatment of Arrhythmias
2:30 Management of atrial fibrillation
Gheorghe-Andrei Dan
2:50 Management of ventricular arrhythmias
Ali Oto
3:10 Break
Management of Acute conditions: Pharmacologic Strategies and New Drugs
Co-chair: Gheorghe-Andrei Dan
Co-chair: Zhu Jun
3:30 Acute coronary syndromes
Nicolas Danchin
3:50 Acute heart failure
Willem Remme
4:10 Medical therapy of acute ST-elevation MI
Dennis Cokkinos
4:30 Adjourn
MONDAY, OCTOBER 12, 2009
Restoring Health to the Heart and Vasculature
Co-chair: Daniel Duprez
Co-chair: Gao Runlin
9:00 Is vascular stiffness a target for therapy?
Daniel Duprez
9:20 Prevention and regression of myocardial remodeling
Dennis Cokkinos
9:40 Drugs to relieve myocardial ischemia
Alex Battler
10:00 Relative benefit of blood pressure reduction in reducing cardiovascular risk
William Louis
10:20 Discussion
10:30 Break
Controversies in Cardiovascular Therapy I
Co-chair: Miran Kenda
Co-chair: Chen Yundai
11:00 Is pharmacotherapy appropriate in the elderly?
Miran Kenda
11:20 What is the best regimen for inhibiting the renin-angiotensin system?
Felipe Martinez
11:40 Drug therapy vs. mechanical reperfusion in chronic stable angina
Alex Battler
12:00 Lunch
Controversies in Cardiovascular Therapy II
Co-chair: Juan Carlos Kaski
Co-chair: Hu Dayi
1:30 How to best identify candidates for pharmacoprevention
Jay N. Cohn
1:50 Should aspirin be used for primary prevention?
John McNeil
2:10 Is HDL still a target for therapy?
Rodolfo Paoletti
2:30 Secondary prevention of CAD with ACE inhibitors: Struggle between life and death of the endothelium
Roberto Ferrari
2:50 Do oral anti-diabetic drugs reduce cardiovascular disease risk?
Daniel Duprez
3:10 Do new antianginal drugs represent a therapeutic advance?
Juan Carlos Kaski
3:30 Critical issues in the ACC/AHA secondary prevention guidelines
Sidney Smith
3:50 Adjourn
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cohn, J.N. President’s Page: Beijing 2009. Cardiovasc Drugs Ther 23, 419–423 (2009). https://doi.org/10.1007/s10557-009-6193-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-009-6193-4